Shares of Nivalis Therapeutics, Inc. (NASDAQ:ALPN) have received an average rating of “Hold” from the nine analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $6.35.

Several equities research analysts recently weighed in on the company. Zacks Investment Research downgraded Nivalis Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, October 26th. ValuEngine downgraded Nivalis Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Finally, Ladenburg Thalmann Financial Services assumed coverage on Nivalis Therapeutics in a report on Thursday, July 27th. They set a “buy” rating and a $17.00 price objective on the stock.

TRADEMARK VIOLATION NOTICE: “Nivalis Therapeutics, Inc. (ALPN) Receives $6.35 Average PT from Brokerages” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at

Nivalis Therapeutics (NASDAQ:ALPN) traded up $0.23 during midday trading on Thursday, hitting $10.25. The company had a trading volume of 57,000 shares, compared to its average volume of 30,999. The company has a debt-to-equity ratio of 0.05, a quick ratio of 32.38 and a current ratio of 32.38. Nivalis Therapeutics has a 12 month low of $7.20 and a 12 month high of $26.08.

A hedge fund recently bought a new stake in Nivalis Therapeutics stock. Sowell Financial Services LLC bought a new position in shares of Nivalis Therapeutics, Inc. (NASDAQ:ALPN) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 15,714 shares of the biotechnology company’s stock, valued at approximately $162,000. Sowell Financial Services LLC owned 0.40% of Nivalis Therapeutics at the end of the most recent quarter.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:ALPN)

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.